DUOS TECHNOLOGIES GROUP INC (DUOT)

US2660424076 - Common Stock

4.58  -0.31 (-6.34%)

After market: 4.3107 -0.27 (-5.88%)

Fundamental Rating

1

DUOT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 280 industry peers in the Software industry. DUOT has a bad profitability rating. Also its financial health evaluation is rather negative. DUOT is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year DUOT has reported negative net income.
DUOT had a negative operating cash flow in the past year.
DUOT had negative earnings in each of the past 5 years.
In the past 5 years DUOT always reported negative operating cash flow.

1.2 Ratios

DUOT has a Return On Assets of -56.88%. This is amonst the worse of the industry: DUOT underperforms 87.46% of its industry peers.
DUOT has a Return On Equity of -422.83%. This is amonst the worse of the industry: DUOT underperforms 86.38% of its industry peers.
Industry RankSector Rank
ROA -56.88%
ROE -422.83%
ROIC N/A
ROA(3y)-67.78%
ROA(5y)-70.66%
ROE(3y)-383.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 7.28%, DUOT is not doing good in the industry: 88.53% of the companies in the same industry are doing better.
DUOT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for DUOT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y80.38%
GM growth 5Y-16.5%

1

2. Health

2.1 Basic Checks

DUOT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DUOT has more shares outstanding
Compared to 5 years ago, DUOT has more shares outstanding
Compared to 1 year ago, DUOT has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -5.06, we must say that DUOT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.06, DUOT is not doing good in the industry: 86.02% of the companies in the same industry are doing better.
DUOT has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
DUOT's Debt to Equity ratio of 0.08 is in line compared to the rest of the industry. DUOT outperforms 52.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -5.06
ROIC/WACCN/A
WACC11.92%

2.3 Liquidity

A Current Ratio of 0.59 indicates that DUOT may have some problems paying its short term obligations.
The Current ratio of DUOT (0.59) is worse than 90.68% of its industry peers.
A Quick Ratio of 0.41 indicates that DUOT may have some problems paying its short term obligations.
The Quick ratio of DUOT (0.41) is worse than 94.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.41

4

3. Growth

3.1 Past

The earnings per share for DUOT have decreased strongly by -48.21% in the last year.
Looking at the last year, DUOT shows a very negative growth in Revenue. The Revenue has decreased by -60.74% in the last year.
Measured over the past years, DUOT shows a decrease in Revenue. The Revenue has been decreasing by -9.12% on average per year.
EPS 1Y (TTM)-48.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.38%
Revenue 1Y (TTM)-60.74%
Revenue growth 3Y-2.42%
Revenue growth 5Y-9.12%
Sales Q2Q%-14.66%

3.2 Future

The Earnings Per Share is expected to grow by 34.84% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 58.45% on average over the next years. This is a very strong growth
EPS Next Y25.29%
EPS Next 2Y34.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year36.62%
Revenue Next 2Y58.45%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

DUOT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DUOT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DUOT's earnings are expected to grow with 34.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.84%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

DUOT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

DUOS TECHNOLOGIES GROUP INC

NASDAQ:DUOT (11/22/2024, 8:00:00 PM)

After market: 4.3107 -0.27 (-5.88%)

4.58

-0.31 (-6.34%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap36.78M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.88%
ROE -422.83%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 7.28%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.59
Quick Ratio 0.41
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-48.21%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y25.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-60.74%
Revenue growth 3Y-2.42%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y